Complex clinical encounter series: glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?

Ambrogini E

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Aug 2026

PMID41989133DOI10.1093/jbmr/zjag069PepBankPUB-41989133

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesEfficacy outcome
In a 65-year-old woman with obesity, about 15% of body weight was lost after 1 year on subcutaneous semaglutide.
In plain wordsOne 65-year-old woman with obesity lost about 15% of her weight after 1 year on semaglutide.
Peptide
Semaglutide
Outcome
DecreaseWeight loss
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 1 yearAs given in this study (human).
Measurements
Weight loss
≈ 15%
after 1 yr
Source sentences
Summary
After 1 yr on semaglutide, she lost ~15% of her weight with improvement of blood pressure, lipid profile, and sleeping pattern.
1 context sentence(design, population, supporting numbers)
Summary · context
A 65-yr-old White woman with obesity class II, hypertension, hyperlipidemia, obstructive sleep apnea, osteoarthritis, and pre-diabetes was started on s.c. semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), for weight loss.
Report a problemFND-4198913301
02HumanCase report or seriesEfficacy outcome
In a 65-year-old woman with obesity, blood pressure improved after 1 year on semaglutide.
In plain wordsOne woman's blood pressure improved after 1 year on semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedBlood pressure
Study
n = 1
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 1 yearAs given in this study (human).
Source sentences
Summary
After 1 yr on semaglutide, she lost ~15% of her weight with improvement of blood pressure, lipid profile, and sleeping pattern.
1 context sentence(design, population, supporting numbers)
Summary · context
A 65-yr-old White woman with obesity class II, hypertension, hyperlipidemia, obstructive sleep apnea, osteoarthritis, and pre-diabetes was started on s.c. semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), for weight loss.
Report a problemFND-4198913302
03HumanCase report or seriesEfficacy outcome
In a 65-year-old woman with obesity, the lipid profile improved after 1 year on semaglutide.
In plain wordsOne woman's blood fat levels improved after 1 year on semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedLipid profile
Study
n = 1
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 1 yearAs given in this study (human).
Source sentences
Summary
After 1 yr on semaglutide, she lost ~15% of her weight with improvement of blood pressure, lipid profile, and sleeping pattern.
1 context sentence(design, population, supporting numbers)
Summary · context
A 65-yr-old White woman with obesity class II, hypertension, hyperlipidemia, obstructive sleep apnea, osteoarthritis, and pre-diabetes was started on s.c. semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), for weight loss.
Report a problemFND-4198913303
04HumanCase report or seriesEfficacy outcome
In a 65-year-old woman with obesity and sleep apnea, the sleeping pattern improved after 1 year on semaglutide.
In plain wordsOne woman's sleep improved after 1 year on semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedSleeping pattern
Study
n = 1
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · subcutaneous · 1 yearAs given in this study (human).
Source sentences
Summary
After 1 yr on semaglutide, she lost ~15% of her weight with improvement of blood pressure, lipid profile, and sleeping pattern.
1 context sentence(design, population, supporting numbers)
Summary · context
A 65-yr-old White woman with obesity class II, hypertension, hyperlipidemia, obstructive sleep apnea, osteoarthritis, and pre-diabetes was started on s.c. semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), for weight loss.
Report a problemFND-4198913304
05HumanCase report or seriesSafety outcome
A 65-year-old woman with obesity reported 2 recent falls after 1 year on subcutaneous semaglutide.
In plain wordsOne 65-year-old woman reported 2 recent falls after 1 year on semaglutide. One case cannot show semaglutide caused them.
Peptide
Semaglutide
Outcome
Direction not reportedFalls
Study
n = 1
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 1 yearAs given in this study (human).
Source sentences
Summary
She reports 2 recent falls.
Report a problemFND-4198913305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.